The Impact of NOACS versus VKAS on Absolute and Relative Cognitive Function Decline Over Time: A Machine Learning Approach
Research article published in Thrombosis and haemostasis (2025)
Abstract
Atrial fibrillation (AF) is the most common arrhythmia in older adults and is associated with an increased risk of cognitive impairment and dementia, even in patients without prior stroke. Nonvitamin K antagonist oral anticoagulants (NOACs) offer a better safety profile than vitamin K antagonists (VKAs), but their cognitive benefit remains uncertain.To assess the impact of NOACs versus VKAs on cognitive decline in elderly AF patients using a machine learning approach.This multicenter prospective cohort study included 983 AF outpatients enrolled between 2008 and 2022 at the Geriatrics Department, University of Catanzaro, and the ProMISE Department, University of Palermo. Stroke and bleeding risks were assessed using CHA2DS2-VASc and HAS-BLED scores. Cognitive function was evaluated using the Mini-Mental State Examination (MMSE). Cognitive decline was defined as a decrease in MMSE score between baseline and follow-up. Patients with prior anticoagulant therapy (OAT), severe dementia, or comorbidities affecting cognition were excluded. Multivariable logistic regression and a random forest classifier were used to assess whether anticoagulant type independently predicted cognitive decline. Class imbalance was addressed using both class-weighted learning and the synthetic minority over-sampling technique (SMOTE), with model performance evaluated through repeated stratified cross-validation and threshold optimization.At baseline, cognitive performance was comparable between groups (p = 0.11). After a mean follow-up of 7.2 ± 3.4 years, MMSE scores declined significantly more in VKA-treated patients (-1.7 vs. -0.3 points, p < 0.001). In logistic regression, NOAC use was independently associated with a lower risk of cognitive decline (odds ratio: 0.322; 95% confidence interval: 0.221-0.469; p < 0.0001). The random forest classifier achieved a mean cross-validated AUC of 0.8719 (standard deviation: 0.0273) and a test-set AUC of 0.880. Threshold adjustment and SMOTE improved sensitivity (recall increased: 0.47-0.84), with a precision-recall AUC of 0.763. Permutation importance analysis identified "OAT" as the top predictor. Predicted probabilities of cognitive decline were significantly higher in VKA users (median = 0.70) than in NOAC users (median = 0.09), confirmed by a Kolmogorov-Smirnov test (KS = 0.385, p < 0.001).NOAC use is associated with a lower predicted probability of cognitive decline, suggesting potential cognitive benefits over VKAs.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Atrial fibrillation (AF) is the most common arrhythmia in older adults and is associated with an increased risk of cognitive impairment and dementia, even in patients without prior stroke. Nonvitamin K antagonist oral anticoagulants (NOACs) offer a better safety profile than vitamin K antagonists (VKAs), but their cognitive benefit remains uncertain.
Por qué esto importa para la hirudoterapia
Esta cohorte prospectiva multicéntrica de 983 pacientes ambulatorios ancianos con fibrilación auricular utilizó regresión logística y un modelo de random-forest para comparar el deterioro cognitivo en anticoagulantes orales no dependientes de la vitamina K (NOACs) frente a antagonistas de la vitamina K (VKAs); durante un seguimiento medio de 7,2 años, las puntuaciones del MMSE disminuyeron significativamente más en los pacientes tratados con VKA (-1,7 frente a -0,3 puntos) y el uso de NOAC se asoció independientemente con menores probabilidades de deterioro (OR 0,322). Para ASH, el valor es contextual en lugar de directo: documenta la carga a largo plazo y las compensaciones dependientes de la clase de la anticoagulación oral sistémica frente a las cuales a veces se posicionan los antitrombóticos derivados de la sanguijuela medicinal (hirudin, calin, destabilase), subrayando por qué el secretoma de la sanguijuela sigue siendo de interés para el descubrimiento de fármacos como fuente de péptidos anticoagulantes localizados y mecánicamente distintos. Advertencia honesta: se trata de una cohorte observacional con un análisis de aprendizaje automático que muestra asociación, no causalidad, y estudia únicamente anticoagulantes orales farmacéuticos; no realiza ninguna afirmación sobre las sanguijuelas o la hirudoterapia y no puede interpretarse como evidencia de ningún tratamiento basado en sanguijuelas.
Citación
The Impact of NOACS versus VKAS on Absolute and Relative Cognitive Function Decline Over Time: A Machine Learning Approach.
Ferrantelli S et al. · Thrombosis and haemostasis, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026